Samuel Isaly
SKIPOrbiMed Advisors
Pioneering healthcare-dedicated investment platform with $18B AUM but too diversified, event-driven, and institutional to align with our concentrated value approach.
Healthcare & Biotech Specialists
Score Breakdown
Investment Philosophy & Portfolio Style
Philosophy
OrbiMed takes a multi-strategy approach to healthcare investing. On the public equity side, the firm runs long/short event-driven strategies focused on clinical catalysts, FDA approvals, and M&A in biotech and pharma. On the private side, OrbiMed makes venture and growth equity investments in early-to-mid stage biotech and medtech companies. The philosophy is deeply science-driven — the team includes MDs, PhDs, and scientists who can evaluate clinical trial data and drug pipelines. OrbiMed emphasizes domain expertise and information advantage within healthcare. The firm aims for responsible, sustainable growth and long-term shareholder value, but the public equity fund is more actively traded around catalysts than a pure buy-and-hold approach.
Portfolio Style
Highly diversified across healthcare sub-sectors. The public equity fund runs long/short with moderate concentration — typically 50-100+ positions. The firm's overall AUM (~$18B) spans venture capital, growth equity, public equity, and credit. The public equity strategy trades around clinical and regulatory catalysts (FDA decisions, trial readouts). The venture/PE side is genuinely long-term (5-10 year holds in private companies through IPO and beyond). Portfolio is almost exclusively healthcare — no diversification outside the sector. The firm's scale makes it one of the most important healthcare-dedicated pools of capital globally.
Background
Samuel Isaly founded OrbiMed Advisors in 1989, making it one of the oldest and largest healthcare-dedicated investment firms in the world. Isaly had prior experience in healthcare equity research and investment banking. OrbiMed has grown to manage approximately $18 billion in assets across public equity, private equity, venture capital, and credit strategies focused exclusively on healthcare, biotech, medical devices, and diagnostics. The firm has offices in New York, San Francisco, Shanghai, Herzliya (Israel), Mumbai, Hong Kong, and London. OrbiMed's venture portfolio has backed 110+ life science startups and contributed to 80+ new healthcare therapies reaching patients. Isaly stepped back from day-to-day management in recent years, with a deep team continuing operations.
Track Record
OrbiMed has been investing in healthcare for 35+ years, making it one of the longest-tenured firms in the space. The venture portfolio has produced strong returns with 80+ therapies reaching patients and numerous successful exits via IPO or M&A. The public equity hedge fund has had more mixed results — biotech long/short strategies are notoriously volatile, and the fund has experienced significant drawdowns during biotech selloffs (2015-2016, 2021-2022). The firm's staying power and continued growth to $18B AUM over three decades demonstrates sustained institutional confidence. However, detailed public equity fund returns are not publicly available. The firm's greatest strength may be its private/venture side rather than its public equity trading.
Notable Holdings
OrbiMed's public equity portfolio has historically included major biotech names across the market cap spectrum. Positions have included companies like BioMarin, Sarepta Therapeutics, Exact Sciences, Jazz Pharmaceuticals, and numerous mid/small-cap biotech names. The venture portfolio has backed companies across oncology, rare disease, gene therapy, and medtech. Due to the diversified, multi-strategy nature of the firm, no single position defines OrbiMed the way concentrated investors are defined by their top holdings.
Transparency & Integrity
Transparency(Score: 4/10)
Low to moderate. OrbiMed files 13F reports for its public equity holdings. However, as a multi-strategy private firm, most of its activities (venture, PE, credit) are not publicly disclosed. The firm does not publicize performance numbers. Isaly has been a relatively private figure compared to more media-savvy hedge fund managers. The firm's website provides general information about strategy and team but little detail on returns or specific portfolio construction.
Integrity(Score: 7/10)
Good institutional reputation. OrbiMed has operated for 35 years without major scandals or SEC enforcement actions. The firm has committed over $2 billion to developing-country healthcare initiatives, showing genuine commitment beyond profit extraction. The science-driven approach and long tenure suggest intellectual honesty. No notable controversies. However, the healthcare long/short space generally carries some risk of trading around material non-public information from clinical trials, though no such allegations have been made against OrbiMed.
Relevance to Us
Low alignment. OrbiMed is a large institutional platform, not a concentrated value investor. The firm's public equity approach is event-driven and catalyst-focused (FDA decisions, clinical trials), which is essentially binary bet-making rather than patient value investing. The diversification across 50-100+ positions and long/short structure is the opposite of our concentrated, long-only approach. The venture/PE side is more interesting from a long-term perspective but is not accessible to us. OrbiMed's healthcare expertise is vast, but the way it deploys capital does not match our philosophy. Following their 13F would expose us to a highly diversified, event-driven portfolio that is fundamentally different from what we seek.